These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24080666)

  • 1. In vitro activity of Ozenoxacin against quinolone-susceptible and quinolone-resistant gram-positive bacteria.
    López Y; Tato M; Espinal P; Garcia-Alonso F; Gargallo-Viola D; Cantón R; Vila J
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6389-92. PubMed ID: 24080666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microbiological profile of ozenoxacin.
    Morrissey I; Cantón R; Vila J; Gargallo-Viola D; Zsolt I; Garcia-Castillo M; López Y
    Future Microbiol; 2019 Jun; 14():773-787. PubMed ID: 31132895
    [No Abstract]   [Full Text] [Related]  

  • 3. In vitro selection of mutants resistant to ozenoxacin compared with levofloxacin and ciprofloxacin in Gram-positive cocci.
    López Y; Tato M; Espinal P; Garcia-Alonso F; Gargallo-Viola D; Cantón R; Vila J
    J Antimicrob Chemother; 2015 Jan; 70(1):57-61. PubMed ID: 25261416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of variables that may influence ozenoxacin in susceptibility testing, including MIC and MBC values.
    Tato M; López Y; Morosini MI; Moreno-Bofarull A; Garcia-Alonso F; Gargallo-Viola D; Vila J; Cantón R
    Diagn Microbiol Infect Dis; 2014 Mar; 78(3):263-7. PubMed ID: 24321353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro antimicrobial activity of ozenoxacin against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus and Streptococcus pyogenes isolated from clinical cutaneous specimens in Japan.
    Kanayama S; Ikeda F; Okamoto K; Nakajima A; Matsumoto T; Ishii R; Amano A; Matsuzaki K; Matsumoto S
    J Infect Chemother; 2016 Oct; 22(10):720-3. PubMed ID: 27091753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bactericidal activity and post-antibiotic effect of ozenoxacin against Propionibacterium acnes.
    Kanayama S; Okamoto K; Ikeda F; Ishii R; Matsumoto T; Hayashi N; Gotoh N
    J Infect Chemother; 2017 Jun; 23(6):374-380. PubMed ID: 28389164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ozenoxacin: A Novel Drug Discovery for the Treatment of Impetigo.
    Sahu JK; Mishra AK
    Curr Drug Discov Technol; 2019; 16(3):259-264. PubMed ID: 29732990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical Ozenoxacin Cream 1% for Impetigo: A Review.
    Schachner L; Andriessen A; Bhatia N; Grada A; Patele D
    J Drugs Dermatol; 2019 Jul; 18(7):655-661. PubMed ID: 31334625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ozenoxacin: A novel topical antibiotic.
    Santhosh P; Thomas MH
    Indian J Dermatol Venereol Leprol; 2021; 87(1):131-134. PubMed ID: 33580932
    [No Abstract]   [Full Text] [Related]  

  • 10. Antimicrobial activities of ozenoxacin against isolates of propionibacteria and staphylococci from Japanese patients with acne vulgaris.
    Nakajima A; Ikeda F; Kanayama S; Okamoto K; Matsumoto T; Ishii R; Fujikawa A; Takei K; Kawashima M
    J Med Microbiol; 2016 Aug; 65(8):745-750. PubMed ID: 27305898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationship in the oxazolidinone-quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action.
    Hubschwerlen C; Specklin JL; Baeschlin DK; Borer Y; Haefeli S; Sigwalt C; Schroeder S; Locher HH
    Bioorg Med Chem Lett; 2003 Dec; 13(23):4229-33. PubMed ID: 14623007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.
    Nilius AM; Shen LL; Hensey-Rudloff D; Almer LS; Beyer JM; Balli DJ; Cai Y; Flamm RK
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3260-9. PubMed ID: 14506039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ozenoxacin: A Novel Topical Quinolone for Impetigo.
    Wren C; Bell E; Eiland LS
    Ann Pharmacother; 2018 Dec; 52(12):1233-1237. PubMed ID: 29962213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.
    Okumura R; Hirata T; Onodera Y; Hoshino K; Otani T; Yamamoto T
    J Antimicrob Chemother; 2008 Jul; 62(1):98-104. PubMed ID: 18390884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
    Lauderdale TL; Shiau YR; Lai JF; Chen HC; King CH
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1338-42. PubMed ID: 20065058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ozenoxacin: a review of preclinical and clinical efficacy.
    Vila J; Hebert AA; Torrelo A; López Y; Tato M; García-Castillo M; Cantón R
    Expert Rev Anti Infect Ther; 2019 Mar; 17(3):159-168. PubMed ID: 30686133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro Antibacterial Activity of 7-Substituted-6-Fluoroquinolone and 7-Substituted-6,8-Difluoroquinolone Derivatives.
    Leyva-Ramos S; de Loera D; Cardoso-Ortiz J
    Chemotherapy; 2017; 62(3):194-198. PubMed ID: 28334702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant prevention concentration of ozenoxacin for quinolone-susceptible or -resistant Staphylococcus aureus and Staphylococcus epidermidis.
    López Y; Tato M; Gargallo-Viola D; Cantón R; Vila J; Zsolt I
    PLoS One; 2019; 14(10):e0223326. PubMed ID: 31596898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative activities of clinafloxacin against gram-positive and -negative bacteria.
    Ednie LM; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1998 May; 42(5):1269-73. PubMed ID: 9593165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative activity of ozenoxacin and other quinolones in Staphylococcus aureus strains overexpressing the efflux pump-encoding genes mepA and norA.
    López Y; Tato M; Gargallo-Viola D; Cantón R; Vila J; Zsolt I
    Int J Antimicrob Agents; 2020 Sep; 56(3):106082. PubMed ID: 32659467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.